1 / 28

Comparative Analysis of US and European Guidelines on Oral Antiplatelet Therapy in Primary PCI/STEMI

This study explores and compares guidelines for oral antiplatelet therapy in primary PCI/STEMI between the US and Europe. It evaluates the use of GP IIb/IIIa inhibitors, bleeding outcomes at 30 days, and primary efficacy outcomes at 48 hours. The outcomes of various trials and analyses such as EUROMAX, HORIZONS-AMI, and CHAMPION PHOENIX are examined to provide insights into treatment strategies and efficacy in acute coronary syndromes.

hailey
Télécharger la présentation

Comparative Analysis of US and European Guidelines on Oral Antiplatelet Therapy in Primary PCI/STEMI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Comparison of US and European Guidelines

  2. Oral Antiplatelet Therapy in Primary PCI/STEMI

  3. GP IIb/IIIa Inhibitors in Primary PCI/STEMI

  4. EUROMAXBleeding Outcomes at 30 d

  5. HORIZONS-AMIBleeding Outcomes at 30 d in a Primary PCI Population

  6. CHAMPION PHOENIX Primary Efficacy Outcomes at 48 h, MITT

  7. Anticoagulation in Primary PCI/STEMI

  8. FUTURA/OASIS 8

  9. Oral Antiplatelet Therapy in Non-ST Elevation ACS

  10. CHARISMABleeding End Points by Baseline Daily Aspirin Dose

  11. CURRENTEfficacy and Bleeding by Aspirin Dose

  12. EARLY-ACSBleeding Outcomes at 30 days

  13. GP IIb/IIIa Inhibitors in Primary PCI/Non-ST-segment Elevation ACS

  14. PLATO SubanalysisEfficacy and Safety End Points

  15. Anticoagulation in Non-ST-segment Elevation ACS

  16. OASIS 5 -- Cumulative Risk of Death, MI, or Refractory Ischemia

  17. The Future for ACS Management?

  18. Abbreviations

  19. Abbreviations (cont)

  20. References

  21. References (cont)

  22. References (cont)

  23. References (cont)

  24. References (cont)

More Related